Article ID Journal Published Year Pages File Type
2794847 Cytokine 2010 6 Pages PDF
Abstract

Recombinant human erythropoietin (rhEPO) has demonstrated beneficial effects against vasospasm and brain damage at the late stage of subarachnoid hemorrhage (SAH); however few investigations have been done about the effect of rhEPO on SAH-induced early brain injury (EBI) and also the underlying mechanisms remain unclear. This study was undertaken to evaluate the influence of rhEPO on the nuclear factor erythroid 2-related factor 2 and antioxidant responsive element (Nrf2–ARE) pathway and early brain injury in rats after SAH. Adult male SD rats were divided into four groups: (1) control group (n = 18); (2) SAH group (n = 18); (3) SAH + vehicle group (n = 18); and (4) SAH + rhEPO group (n = 18). The rat SAH model was induced by injection of 0.3 ml fresh arterial, non-heparinized blood into the prechiasmatic cistern in 20 s. In SAH + rhEPO group, rhEPO was administered i.p. at 1000 U/kg starting 5 min after the induction of SAH and repeated every 8 h for 48 h. Brain samples were extracted at 48 h after SAH. As a result, we found that treatment with rhEPO markedly increased expressions of Nrf2–ARE pathway related agents, such as Nrf2, heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1), and glutathione S-transferase α-1 (GST-α1). Administration of rhEPO following SAH significantly ameliorated EBI, such as cortical apoptosis, brain edema, and blood–brain barrier (BBB) impairment. In conclusion, post-SAH rhEPO administration may attenuate EBI in this SAH model, possibly through activating Nrf2–ARE pathway and modulating cerebral oxidative stress by inducing antioxidant and detoxifying enzymes.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , , , ,